These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 26564936)

  • 21. [PDE-5 inhibitors: patients preferences].
    Efremov EA; Kasatonova EV; Melnik YI; Nikushina AA
    Urologiia; 2017 Jul; (3):120-126. PubMed ID: 28845950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral phosphodiesterase type 5 inhibitors and priapism: A VigiBase analysis.
    Abbasi B; Shaw NM; Lui JL; Hakam N; Nabavizadeh B; Breyer BN
    Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5721. PubMed ID: 37909414
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Are We Overstating the Risk of Priapism With Oral Phosphodiesterase Type 5 Inhibitors?
    Rezaee ME; Gross MS
    J Sex Med; 2020 Aug; 17(8):1579-1582. PubMed ID: 32622767
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunction.
    Rubio-Aurioles E; Porst H; Kim ED; Montorsi F; Hackett G; Morales AM; Stuckey B; Būttner H; West TM; Huynh NN; Lenero E; Burns P; Kopernicky V
    J Sex Med; 2012 May; 9(5):1418-29. PubMed ID: 22429760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A case of hypoglycemia due to illegitimate sexual enhancement medication.
    Kuramoto N; Yabe D; Kurose T; Seino Y
    Diabetes Res Clin Pract; 2015 Apr; 108(1):e8-e10. PubMed ID: 25748828
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction.
    Mulhall JP; McLaughlin TP; Harnett JP; Scott B; Burhani S; Russell D
    J Sex Med; 2005 Nov; 2(6):848-55. PubMed ID: 16422809
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of sildenafil citrate (Viagra) and tadalafil (Cialis) on sexual responses in Saudi men with erectile dysfunction in routine clinical practice.
    Ali ST
    Pak J Pharm Sci; 2008 Jul; 21(3):275-81. PubMed ID: 18614424
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Dosage forms of sildenafil in the management of erectile dysfunction].
    Grigoryan VA; Gazimiev MA; Demidko YL; Baiduvaliev AM
    Urologiia; 2018 Mar; (1):159-162. PubMed ID: 29634153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 10-Year analysis of adverse event reports to the Food and Drug Administration for phosphodiesterase type-5 inhibitors.
    Lowe G; Costabile RA
    J Sex Med; 2012 Jan; 9(1):265-70. PubMed ID: 22023666
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between sexual activity-related death and non-prescription use of phosphodiesterase type 5 inhibitors.
    Nagasawa S; Saka K; Yamagishi Y; Yajima D; Chiba F; Yamaguchi R; Torimitsu S; Iwase H
    Leg Med (Tokyo); 2021 Feb; 48():101815. PubMed ID: 33264696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Phosphodesterase type 5 inhibitors clinical efficiency and role in therapy for erectile dysfunction].
    Shodmonova ZR; Gafarov RR; Allazov SA; Giyasov SI
    Urologiia; 2021 May; (2):135-140. PubMed ID: 33960173
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute pancreatitis induced by Tadalafil: a case report.
    Navabi SJ; Khosravifar M; Navabi SM; Heydari R
    Clin J Gastroenterol; 2020 Jun; 13(3):459-464. PubMed ID: 31797202
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Central serous chorioretinopathy following the use of phosphodiesterase 5 inhibitors].
    Smal C; Lepièce G; Bonnet S
    Rev Med Liege; 2017 Nov; 72(11):475-477. PubMed ID: 29171944
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amelioration of untreated restless legs syndrome by tadalafil in a patient with erectile dysfunction.
    Romigi A; Vitrani G; D'Aniello A; Di Gennaro G
    Clin Neuropharmacol; 2015; 38(2):62. PubMed ID: 25768855
    [No Abstract]   [Full Text] [Related]  

  • 35. Comparison between counterfeit and authentic medicines: A novel approach using differential scanning calorimetry and hierarchical cluster analysis.
    Dos Santos MK; de Cassia Mariotti K; Kahmann A; Anzanello MJ; Ferrão MF; de Araújo Gomes A; Limberger RP; Ortiz RS
    J Pharm Biomed Anal; 2019 Mar; 166():304-309. PubMed ID: 30685655
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patient diagnosed with chronic erectile dysfunction refractory to PDE 5 Inhibitor therapy reports improvement in function after hyperbaric oxygen therapy.
    Cormier J; Theriot M
    Undersea Hyperb Med; 2016; 43(4):463-465. PubMed ID: 28763176
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Serous central chorioretinopathy and tadalafil: a case report].
    Nadeau S; Nguyen F; Guigou S
    J Fr Ophtalmol; 2012 Feb; 35(2):121.e1-5. PubMed ID: 21680058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension].
    Beltrán-Gámez ME; Sandoval-Zárate J; Pulido T
    Arch Cardiol Mex; 2015; 85(3):215-24. PubMed ID: 26047999
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treating erectile dysfunction and central neurological diseases with oral phosphodiesterase type 5 inhibitors. Review of the literature.
    Lombardi G; Nelli F; Celso M; Mencarini M; Del Popolo G
    J Sex Med; 2012 Apr; 9(4):970-85. PubMed ID: 22304626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-arteritic anterior ischemic optic neuropathy (NAION) and phosphodiesterase type-5 inhibitors.
    Bella AJ; Brant WO; Lue TF; Brock GB
    Can J Urol; 2006 Oct; 13(5):3233-8. PubMed ID: 17076943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.